A Phase 1 interventional study of Metformin/Gliclazide Fixed Combination in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Mexico. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-08.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the food effect on bioavailability of Metformin/Gliclazide fixed dose combination tablet in fed and fasted state.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
Drug: Metformin/Gliclazide Fixed Combination
Participants received single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 2. Each treatment period will be separated by a 14-day wash-out period.
Drug: Metformin/Gliclazide Fixed Combination
Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin and Gliclazide
AUC (0-inf) is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Time frame: Pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 28.0, 32.0, 48.0, 72.0, 96.0, 120.0, 144.0 and 168.0 hour post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin and Gliclazide
AUC (0-t) is defined as the area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
Time frame: Pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 28.0, 32.0, 48.0, 72.0, 96.0, 120.0, 144.0 and 168.0 hour post-dose
Maximum Observed Plasma Concentration (Cmax) of Metformin and Gliclazide
Cmax is defined as the maximum observed plasma concentration.
Time frame: Pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 28.0, 32.0, 48.0, 72.0, 96.0, 120.0, 144.0 and 168.0 hour post-dose
Time to Reach Maximum Plasma Concentration (Tmax) of Metformin and Gliclazide
Tmax is defined as the time to reach maximum plasma concentration.
Time frame: Pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 28.0, 32.0, 48.0, 72.0, 96.0, 120.0, 144.0 and 168.0 hour post-dose
Elimination Half Life (t1/2) of Metformin and Gliclazide
Elimination Half Life (t1/2) is defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: Pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 28.0, 32.0, 48.0, 72.0, 96.0, 120.0, 144.0 and 168.0 hour post-dose
Apparent Volume of Distribution (Vz/f) of Metformin and Gliclazide
Vz/f is defined as apparent volume of distribution during terminal phase after non-intravenous administration
Time frame: Pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 28.0, 32.0, 48.0, 72.0, 96.0, 120.0, 144.0 and 168.0 hour post-dose
Apparent Total Body Clearance (CL/f) of Metformin and Gliclazide From Plasma
CL/f is defined as apparent total clearance of the drug from plasma after oral administration.
Time frame: Pre-dose, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 28.0, 32.0, 48.0, 72.0, 96.0, 120.0, 144.0 and 168.0 hour post-dose
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Day 39
| Milestone | Metformin-Gliclazide (Fasted), Then Metformin-Gliclazide (Fed) | Metformin-Gliclazide (Fed), Then Metformin-Gliclazide (Fasted) |
|---|---|---|
| Started | 10 | 11 |
| Completed | 10 | 11 |
| Not completed | 0 | 0 |
| Milestone | Metformin-Gliclazide (Fasted), Then Metformin-Gliclazide (Fed) | Metformin-Gliclazide (Fed), Then Metformin-Gliclazide (Fasted) |
|---|---|---|
| Started | 10 | 11 |
| Completed | 10 | 10 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
AUC (0-inf) is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
| Nanogram*hour per milliliter (ng*h/mL) | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Metformin | 4974.2507 ± 1599.3290 | 8556.7752 ± 2544.6658 |
| Gliclazide | 21192.1682 ± 9220.3044 | 21815.4021 ± 8369.0107 |
AUC (0-t) is defined as the area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
| ng*h/mL | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Metformin | 4722.4546 ± 1598.1082 | 8298.5628 ± 2422.9059 |
| Gliclazide | 20348.8381 ± 9154.5509 | 20997.1704 ± 8244.2743 |
Cmax is defined as the maximum observed plasma concentration.
| ng/mL | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Metformin | 717.5017 ± 304.8105 | 870.7288 ± 272.6886 |
| Gliclazide | 968.0305 ± 261.8362 | 1013.9753 ± 243.1601 |
Tmax is defined as the time to reach maximum plasma concentration.
| Hours | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Metformin | 3.6698 ± 0.6600 | 7.2389 ± 0.7693 |
| Gliclazide | 6.5254 ± 1.7474 | 8.5238 ± 2.1822 |
Elimination Half Life (t1/2) is defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
| Hours | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Metformin | 6.2547 ± 2.9771 | 7.4892 ± 8.7276 |
| Gliclazide | 16.6222 ± 6.2627 | 17.1044 ± 7.5000 |
Vz/f is defined as apparent volume of distribution during terminal phase after non-intravenous administration
| Milliliter (mL) | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Metformin | 2003389.9474 ± 1157828.4547 | 1200933.2647 ± 949837.2019 |
| Gliclazide | 35189.3864 ± 8855.9499 | 33813.7843 ± 6970.7706 |
CL/f is defined as apparent total clearance of the drug from plasma after oral administration.
| Liters | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Metformin | 226.79 ± 88.58 | 125.93 ± 33.92 |
| Glilclazide | 1.63 ± 0.57 | 1.55 ± 0.52 |
Adverse event(AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Adverse Events | 8 | 7 |
| Serious Adverse Events (SAEs) | 0 | 0 |
Collected over Baseline up to Day 39. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin-Gliclazide (Fasted) | 0/21 (0%) | 0/21 (0%) | 8/21 (38.1%) |
| Metformin-Gliclazide (Fed) | 0/21 (0%) | 0/21 (0%) | 7/21 (33.3%) |
| Event | Metformin-Gliclazide (Fasted) | Metformin-Gliclazide (Fed) |
|---|---|---|
| Elevated triglyceridesInvestigations | 2/21 | 3/21 |
| AnemiaBlood and lymphatic system disorders | 0/21 | 3/21 |
| Elevated total bilirubinInvestigations | 1/21 | 0/21 |
| Elevated direct bilirubinInvestigations | 1/21 | 0/21 |
| Elevated indirect bilirubinInvestigations | 1/21 | 0/21 |
| High cholesterolInvestigations | 1/21 | 0/21 |
| HeadacheNervous system disorders | 1/21 | 0/21 |
| VomitingGastrointestinal disorders | 0/21 | 1/21 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/21 | 0/21 |
| Age, Continuous(Years) | Metformin-Gliclazide (Fasted), Then Metformin-Gliclazide (Fed) | Metformin-Gliclazide (Fed), Then Metformin-Gliclazide (Fasted) | Total |
|---|---|---|---|
| Mean | 37.2 ± 10.9 | 32.5 ± 8.0 | 34.7 ± 9.6 |
| Sex: Female, Male(Participants) | Metformin-Gliclazide (Fasted), Then Metformin-Gliclazide (Fed) | Metformin-Gliclazide (Fed), Then Metformin-Gliclazide (Fasted) | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 7 | 8 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Metformin-Gliclazide (Fasted), Then Metformin-Gliclazide (Fed) | Metformin-Gliclazide (Fed), Then Metformin-Gliclazide (Fasted) | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 11 | 21 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Apr 2018, 1 month.
Results were first posted in Jul 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck KGaA, Darmstadt, Germany →